Active Ingredient(s): Insulin Degludec + Liraglutide
FDA Approved: * November 21, 2016
Pharm Company: * NOVO NORDISK INC
Category: Diabetes

Insulin degludec/liraglutide, sold under the brand name Xultophy, is a fixed-dose combination medication for the treatment of adults with type 2 diabetes to improve glycemic control in combination with diet and exercise.[4][5] It contains insulin degludec and liraglutide.[4][5] It is administered by subcutaneous injection.[4][5] The most common side effects include hypoglycaemia (low blood glucose)... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.